1 to 9 of 17 results

MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world


The Japanese Ministry of Health, Labor and Welfare (MHLW) has said it supports the research and development…

Asia-PacificAstellas PharmaDaiichi SankyoEisaiFinancialHealthcarePharmaceuticalResearchShionogiTakeda PharmaceuticalsTropical diseases

Additional indications in Japan for Diagnogreen and Sawacillin


Japanese drug major Daiichi Sankyo (TYO: 4568) says it has received approval in Japan for a supplemental…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDaiichi SankyoPharmaceuticalRegulationSawacillin

Japanese approval for Regnite and Ranmark


Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Ranbaxy back in black in fourth quarter as US sales soar


India’s biggest pharmaceutical company Ranbaxy Laboratories has reported a profit of $106m for the…

Astellas PharmaDaiichi SankyoFlomaxGenericsGlaxoSmithKlineGlobalGSKMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSankyoTamsulosin HydrochlorideValacyclovir HydrochlorideValtrex

Foreign operations generating greater portion of sales at Japan’s Eisai; report


Headquartered in Japan, Eisai operates in two main business areas: Pharmaceuticals, including ethical…

AciphexAriceptAstellas PharmaDaiichi SankyodonepezilEisaiFinancialKyowa HakkoMarkets & MarketingMGI PharmaPfizerPharmaceuticalRabeprazole SodiumSankyo

Japan's industry execs reiterate need to introduce drug price maintenance system


Drug industry executives in Japan, including Toichi Takenaka, president of the Federation of Pharmaceutical…

Astellas PharmaDaiichi SankyoSankyo

1 to 9 of 17 results

Back to top